Skip to content
Inciteful Med

Validation & Orientation: Understanding ALS

Last updated:

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness and stiffness. While life expectancy averages 2 to 5 years, targeted symptom management and breathing support can significantly improve survival and quality of life.

Key Takeaways

  • • ALS is a progressive neurodegenerative disease that damages both upper and lower motor neurons, leading to stiffness, weakness, and muscle wasting.
  • • While 90% of ALS cases are sporadic, genetic testing is recommended for all patients because up to 10% carry mutations like C9orf72 or SOD1.
  • • Average life expectancy is 2 to 5 years, but this varies widely and symptom management can improve outcomes.
  • • The primary cause of severe complications in ALS is respiratory failure, making breathing support a critical part of care.
  • • Doctors track disease progression using functional scores (ALSFRS-R) and emerging blood biomarkers like neurofilament light (NFL).

Receiving a diagnosis of Amyotrophic Lateral Sclerosis (ALS) is a life-altering event. It is important to know that you are not alone, and while the road ahead is challenging, there is a global community of researchers and clinicians working toward better understanding and treating this disease.

Three Stabilizing Facts

To help orient you in these early days, here are three foundational facts about ALS:

  1. ALS is a progressive neurodegenerative disease: This means it is a condition where motor neurons (the specialized nerve cells that control movement) gradually break down and die over time [1][2].
  2. It is a rare but well-documented condition: The incidence of ALS (the number of new cases diagnosed each year) is approximately 1.5 to 3.8 per 100,000 people [3][4]. While it is considered a rare disease, it is one of the most common motor neuron disorders worldwide.
  3. The cause is often complex: For about 90% of people, the cause is unknown (called sporadic ALS) [5]. In the remaining 5% to 10% of cases, there is a clear genetic link (called familial ALS) involving specific genes like C9orf72 or SOD1 [6][7]. However, up to 10% of people with “sporadic” ALS actually carry a genetic mutation even without a family history, making genetic testing an important step for everyone [8][9].

Understanding the Biological Mechanism

To understand why ALS affects your body the way it does, it helps to look at the two types of “bad actors” involved: upper motor neurons and lower motor neurons. Movement requires a signal to travel from your brain, down your spinal cord, and finally to your muscles.

  • Upper Motor Neurons (UMNs): These nerve cells live in the brain and send signals down to the spinal cord [10][2]. When UMNs are damaged, it can cause muscle stiffness (spasticity) and overactive reflexes [11][12].
  • Lower Motor Neurons (LMNs): These cells live in the brainstem and spinal cord and connect directly to your muscles [10]. When LMNs break down, the muscles they control begin to weaken, twitch (fasciculations), and waste away (atrophy) [11][12].

In ALS, both types of neurons are affected, leading to a combination of stiffness and weakness that eventually spreads throughout the body [13][14].

The Role of Genetics

Even in cases where there is no family history, researchers have identified several “key players” in the genetic landscape of ALS. These mutations disrupt how nerve cells handle proteins and energy:

  • C9orf72: The most common genetic cause, which can also be linked to Frontotemporal Dementia (FTD) [15][16].
  • SOD1: One of the first genes discovered to cause ALS; it involves proteins misfolding and causing toxic stress inside the cell [17][18].
  • TARDBP (TDP-43) and FUS: These genes are responsible for managing RNA (the instructions cells use to make proteins). When they malfunction, toxic clumps of protein build up inside the neurons [19][20].

Looking Ahead: Prognosis and Research

ALS is a serious, life-limiting illness. On average, life expectancy is 2 to 5 years after diagnosis, though this varies significantly from person to person [1][5]. The primary cause of death is usually respiratory failure, as the muscles that control breathing eventually weaken [21][22].

While these statistics are difficult to hear, it is important to know that prognosis is not a fixed destiny. Some individuals live much longer than the average, and clinical care focused on managing symptoms and supporting breathing has been shown to improve both quality of life and survival [23][3]. Research is moving faster than ever before, with new insights into biomarkers like neurofilament light (NFL)—a protein in the blood that helps doctors track the speed of the disease [24]. Every day, scientists are uncovering more about the “why” of ALS, bringing us closer to more effective ways to manage the disease.

Frequently Asked Questions

What is the difference between familial and sporadic ALS?
Sporadic ALS occurs without a known cause and accounts for about 90% of cases. Familial ALS makes up the remaining 5% to 10% and has a clear genetic link, though some people with sporadic ALS may also carry genetic mutations.
Should I get genetic testing for ALS if I have no family history?
Yes, up to 10% of people diagnosed with sporadic ALS actually carry a genetic mutation like C9orf72 or SOD1, even without a family history. Because of this, genetic testing is an important step for everyone diagnosed with the disease.
How do upper and lower motor neurons affect ALS symptoms?
Upper motor neuron damage causes muscle stiffness and overactive reflexes. Lower motor neuron breakdown leads to muscle weakness, twitching, and wasting. ALS affects both types of neurons, causing a combination of these symptoms.
What is the average life expectancy after an ALS diagnosis?
On average, life expectancy is 2 to 5 years after diagnosis, but this varies significantly from person to person. Clinical care focused on managing symptoms and supporting breathing has been shown to improve both quality of life and survival length.
How do doctors track the progression of ALS?
Doctors use functional scoring systems like the ALSFRS-R to monitor symptom changes over time. Additionally, new biomarkers like neurofilament light (NFL) in the blood are helping doctors track the speed of the disease more accurately.

Questions for Your Doctor

  • • What evidence of upper and lower motor neuron involvement did you see in my examination or tests?
  • • Given my diagnosis, can we initiate genetic testing for mutations like C9orf72 or SOD1, even if I don't have a known family history?
  • • What is my current functional score (ALSFRS-R), and how will we use this to track my progression?
  • • Can you explain how my specific symptoms might influence my expected disease course?

Questions for You

  • • When did I first notice changes in my strength, speech, or breathing, and which symptoms appeared first?
  • • Are there any members of my family who had ALS, frontotemporal dementia (FTD), or unexplained muscle weakness?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Announcement: Amyotrophic Lateral Sclerosis (ALS) Awareness Month - May 2016.

    MMWR. Morbidity and mortality weekly report 2016; (65(16)):427 doi:10.15585/mmwr.mm6516a6.

    PMID: 27123890
  2. 2

    Updates on Disease Mechanisms and Therapeutics for Amyotrophic Lateral Sclerosis.

    Nguyen L

    Cells 2024; (13(11)) doi:10.3390/cells13110888.

    PMID: 38891021
  3. 3

    Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015.

    Mehta P, Kaye W, Raymond J, et al.

    MMWR. Morbidity and mortality weekly report 2018; (67(46)):1285-1289 doi:10.15585/mmwr.mm6746a1.

    PMID: 30462626
  4. 4

    Amyotrophic Lateral Sclerosis: New Perpectives and Update.

    Orsini M, Oliveira AB, Nascimento OJ, et al.

    Neurology international 2015; (7(2)):5885 doi:10.4081/ni.2015.5885.

    PMID: 26487927
  5. 5

    CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.

    Mehta P, Horton DK, Kasarskis EJ, et al.

    MMWR. Morbidity and mortality weekly report 2017; (66(50)):1379-1382 doi:10.15585/mmwr.mm6650a3.

    PMID: 29267263
  6. 6

    Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014.

    Mehta P, Kaye W, Raymond J, et al.

    MMWR. Morbidity and mortality weekly report 2018; (67(7)):216-218 doi:10.15585/mmwr.mm6707a3.

    PMID: 29470458
  7. 7

    Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons.

    Sharma R, Khan Z, Mehan S, et al.

    Mutation research. Reviews in mutation research 2024; (794()):108518 doi:10.1016/j.mrrev.2024.108518.

    PMID: 39491718
  8. 8

    Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis.

    Akbari Dilmaghani N, Hussen BM, Nateghinia S, et al.

    Metabolic brain disease 2021; (36(5)):737-749 doi:10.1007/s11011-021-00697-5.

    PMID: 33604874
  9. 9

    Atypical Familial Amyotrophic Lateral Sclerosis Secondary to Superoxide Dismutase 1 Gene Mutation With Coexistent Axonal Polyneuropathy: A Challenging Diagnosis.

    Makkawi S, Alqarni AA, Alghaythee H, et al.

    Cureus 2022; (14(1)):e20989 doi:10.7759/cureus.20989.

    PMID: 35154965
  10. 10

    Upper and Lower Motor Neuron Degenerations Are Somatotopically Related and Temporally Ordered in the Sod1 Mouse Model of Amyotrophic Lateral Sclerosis.

    Marques C, Burg T, Scekic-Zahirovic J, et al.

    Brain sciences 2021; (11(3)) doi:10.3390/brainsci11030369.

    PMID: 33805792
  11. 11

    Autophagy and Motor Neuron Diseases.

    Zhang X, Yang K, Le W

    Advances in experimental medicine and biology 2020; (1207()):53-74 doi:10.1007/978-981-15-4272-5_3.

    PMID: 32671738
  12. 12

    Electrodiagnostic Assessment of Motor Neuron Disease.

    Kang X, Quan D

    Neurologic clinics 2021; (39(4)):1071-1081 doi:10.1016/j.ncl.2021.06.008.

    PMID: 34602215
  13. 13

    Amyotrophic lateral sclerosis; clinical features, differential diagnosis and pathology.

    Van Es MA

    International review of neurobiology 2024; (176()):1-47 doi:10.1016/bs.irn.2024.04.011.

    PMID: 38802173
  14. 14

    Motor Band Sign in Primary Lateral Sclerosis: A Case Report Proposing the Need for an Imaging Biomarker.

    Valaparla VL, Lobaina M, Patel C, Patel AV

    Cureus 2023; (15(3)):e36121 doi:10.7759/cureus.36121.

    PMID: 37065386
  15. 15

    Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

    Ghasemi M, Keyhanian K, Douthwright C

    Cells 2021; (10(2)) doi:10.3390/cells10020249.

    PMID: 33525344
  16. 16

    Role of C9orf72 hexanucleotide repeat expansions in ALS/FTD pathogenesis.

    Geng Y, Cai Q

    Frontiers in molecular neuroscience 2024; (17()):1322720 doi:10.3389/fnmol.2024.1322720.

    PMID: 38318532
  17. 17

    P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis.

    Ruiz-Ruiz C, Calzaferri F, García AG

    Frontiers in molecular neuroscience 2020; (13()):93 doi:10.3389/fnmol.2020.00093.

    PMID: 32595451
  18. 18

    Oxidative Stress as a Therapeutic Target in Amyotrophic Lateral Sclerosis: Opportunities and Limitations.

    Park HR, Yang EJ

    Diagnostics (Basel, Switzerland) 2021; (11(9)) doi:10.3390/diagnostics11091546.

    PMID: 34573888
  19. 19

    Spreading of TDP-43 pathology via pyramidal tract induces ALS-like phenotypes in TDP-43 transgenic mice.

    Ding X, Xiang Z, Qin C, et al.

    Acta neuropathologica communications 2021; (9(1)):15 doi:10.1186/s40478-020-01112-3.

    PMID: 33461623
  20. 20

    Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease.

    Gelon PA, Dutchak PA, Sephton CF

    Frontiers in molecular neuroscience 2022; (15()):1000183 doi:10.3389/fnmol.2022.1000183.

    PMID: 36263379
  21. 21

    SIMpLE: A Mobile Cloud-Based System for Health Monitoring of People with ALS.

    Palumbo A, Ielpo N, Calabrese B, et al.

    Sensors (Basel, Switzerland) 2021; (21(21)) doi:10.3390/s21217239.

    PMID: 34770548
  22. 22

    Motor neuron replacement therapy for amyotrophic lateral sclerosis.

    Liu B, Li M, Zhang L, et al.

    Neural regeneration research 2022; (17(8)):1633-1639 doi:10.4103/1673-5374.332123.

    PMID: 35017408
  23. 23

    Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

    Paganoni S, Karam C, Joyce N, et al.

    NeuroRehabilitation 2015; (37(1)):53-68 doi:10.3233/NRE-151240.

    PMID: 26409693
  24. 24

    Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS.

    McCluskey G, Morrison KE, Donaghy C, et al.

    Life (Basel, Switzerland) 2023; (13(6)) doi:10.3390/life13061301.

    PMID: 37374084

This page provides an educational overview of Amyotrophic Lateral Sclerosis (ALS) for informational purposes only. It does not replace professional medical advice from your neurologist or care team.

Stay up to date

Get notified when new research about Amyotrophic lateral sclerosis is published.

No spam. Unsubscribe anytime.